Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease

Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease

Despite several recent advances in therapy in inflammatory bowel disease (IBD), 5-aminosalicylic acid (5-ASA) therapy has retained its place especially in ulcerative colitis. This consensus on 5-ASA is obtained through a modified Delphi process, and includes guiding statements and recommendations ba...

Full description

Bibliographic Details
Main Authors: Ajit Sood, Vineet Ahuja, Vandana Midha, Saroj Kant Sinha, C. Ganesh Pai, Saurabh Kedia, Varun Mehta, Sawan Bopanna, Philip Abraham, Rupa Banerjee, Shobna Bhatia, Karmabir Chakravartty, Sunil Dadhich, Devendra Desai, Manisha Dwivedi, Bhabhadev Goswami, Kirandeep Kaur, Rajeev Khosla, Ajay Kumar, Ramit Mahajan, S. P. Misra, Kiran Peddi, Shivaram Prasad Singh, Arshdeep Singh
Format: Article
Language:English
Published: Korean Association for the Study of Intestinal Diseases 2020-10-01
Series:Intestinal Research
Subjects:
inflammatory bowel disease
5-aminosalicylic acid
crohn disease
colitis, ulcerative
mesalamine
Online Access:http://www.irjournal.org/upload/pdf/ir-2019-09176.pdf

Internet

http://www.irjournal.org/upload/pdf/ir-2019-09176.pdf

Similar Items